Literature DB >> 22313527

Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine.

Ryoko Hirakawa1, Nesrine El-Bizri, John C Shryock, Luiz Belardinelli, Sridharan Rajamani.   

Abstract

Ranolazine, an anti-anginal drug, reduces neuropathic and inflammatory-induced allodynia in rats. However, the mechanism of ranolazin's anti-allodynic effect is not known. We hypothesized that ranolazine would reduce dorsal root ganglion (DRG) Na(+) current (I(Na)) and neuronal firing by stabilizing Na(+) channels in inactivated states to cause voltage- and frequency-dependent block. Therefore, we investigated the effects of ranolazine on tetrodotoxin-sensitive (TTXs) and tetrodotoxin-resistant (TTXr) I(Na) and action potential parameters of small diameter DRG neurons from embryonic rats. Ranolazine (10 and 30 μM) significantly reduced the firing frequency of evoked action potentials in DRG neurons from 19.2 ± 1.4 to 9.8 ± 2.7 (10 μM) and 5.7 ± 1.3 (30 μM) Hz at a resting membrane potential of -40 mV. Ranolazine blocked TTXs and TTXr in a voltage- and frequency-dependent manner. Furthermore, ranolazine (10 μM) blocked hNa(v)1.3 (expressed in HEK293 cells) and caused a hyperpolarizing shift in the voltage dependence of steady-state intermediate and slow inactivation Na(v)1.3 current. Taken together, the results suggest that ranolazine suppresses the hyperexcitability of DRG neurons by interacting with the inactivated states of Na(+) channels and these actions may contribute to its anti-allodynic effect in animal models of neuropathic pain.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313527     DOI: 10.1016/j.neuropharm.2012.01.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Late sodium current (INaL) in pancreatic β-cells.

Authors:  Riccardo Rizzetto; Marcella Rocchetti; Luca Sala; Carlotta Ronchi; Alice Villa; Mara Ferrandi; Isabella Molinari; Federico Bertuzzi; Antonio Zaza
Journal:  Pflugers Arch       Date:  2014-09-20       Impact factor: 3.657

2.  The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy.

Authors:  Erin M Baker; Christopher H Thompson; Nicole A Hawkins; Jacy L Wagnon; Eric R Wengert; Manoj K Patel; Alfred L George; Miriam H Meisler; Jennifer A Kearney
Journal:  Epilepsia       Date:  2018-05-21       Impact factor: 5.864

3.  Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells.

Authors:  Peter Strege; Arthur Beyder; Cheryl Bernard; Ruben Crespo-Diaz; Atta Behfar; Andre Terzic; Michael Ackerman; Gianrico Farrugia
Journal:  Channels (Austin)       Date:  2012-09-27       Impact factor: 2.581

4.  Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.

Authors:  S Sokolov; C H Peters; S Rajamani; P C Ruben
Journal:  Front Pharmacol       Date:  2013-06-21       Impact factor: 5.810

5.  Analgesic effects of calcitonin on radicular pain in male rats.

Authors:  Yoshinori Terashima; Tsuneo Takebayashi; Shunsuke Jimbo; Izaya Ogon; Tatsuya Sato; Nobutoshi Ichise; Noritsugu Tohse; Toshihiko Yamashita
Journal:  J Pain Res       Date:  2019-01-03       Impact factor: 3.133

Review 6.  Efficacy of medications in adult patients with trigeminal neuralgia compared to placebo intervention: a systematic review with meta-analyses.

Authors:  Georgia M Peterson-Houle; Magda R AbdelFattah; Mariela Padilla; Reyes Enciso
Journal:  J Dent Anesth Pain Med       Date:  2021-10-01

7.  The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor.

Authors:  Tzu-Hsien Chuang; Hsin-Yen Cho; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2021-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.